printMedical maleficence! Medical malpractice—and a testament to the incurious, mediocrities most doctors are: This is how Peter MuCullough, as fine a thinker as he is a clinician, has characterized a consensus among the medical community that, for some reason, COVID-19 (unique among all diseases) is, and must remain, impervious to treatment.
Group think gripping Americans, in general, and institutionalized, intellectual atrophy and ineptness, in particular, have stopped doctors from doing what medicine had always done: come up with a combination of drugs to treat outpatients, and treat them early, so as to reduce hospitalizations and mortality from COVID-19.
Well, rays of freedom are peeking through the clouds. There is a large enough segment of the population which has reserved the right to question vaccines behind which are two months of clinical safety data (most vaccines can take years to approve), no formal FDA approval process, and whose manufacturers are exempt by a corrupt state from liability.
These “foolish,” “irrational,” vaccine-resisters have also surmised rather rationally that, following the vaccination edict will come bullying about a booster, given the waning immune response conferred by Covid vaccines.
So, as corrupt as state-co-opted medicine has become; some free-market incentives are still in operation. All the more so in Japan, where an intelligent population has chosen not to vaccinate, for the most: at about 8%, rates of vaccination in Japan are extremely low.
A Japanese company sees an opportunity; a market for sensible treatment.
The race to develop an oral cure for COVID-19 has just heated up with the announcement that Japanese pharmaceutical company Shionogi has started human trials for its once-a day tablet meant to neutralize the virus in patients. Pfizer and Merck are already in later-stage trials for similar treatments, which are presently missing as a tool to battle the pandemic. Pfizer’s twice-daily treatment could be available by the end of 2021. The advent of a reliable cure would be especially important for those who cannot be vaccinated for health reasons, say medical experts.
Pfizer has said its twice-daily pill could be ready to hit the market as soon as this year. It is preparing to enroll more than 2,000 patients in a test of the antiviral pill combined with a booster antiviral drug against a placebo.
All three companies aim to fill one of the biggest gaps in fighting the pandemic. Vaccines remain effective at preventing serious illness from known strains of the Covid-19 virus including the contagious Delta strain, studies have shown. But some people don’t want to get vaccinated, and cases can occur for those who do get their shots.
Of course, thanks to the pockets of free-market medicine extant in the USA, there are already heroic frontline doctors, fine, courageous and imaginative clinicians—the best of the best—who’re acting to treat patients with an existing arsenal of well-tested and already approved medicines.